文献速递药物相互作用特殊人群用药治疗药物监测与药物基因组学

基于生理药动学模型研究COVID-19患者中伏立康唑与奈玛特韦/利托那韦的疾病-药物-药物相互作用及CYP2C19表型影响

Physiologically Based Pharmacokinetic Modeling to Investigate the Disease-Drug-Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID-19 Patients with CYP2C19 Phenotypes.
PubMed 文献 · Clin Pharmacol Ther · 2024-03-01

该研究建立并验证了生理药动学模型,模拟COVID-19伴IL-6升高患者中伏立康唑与奈玛特韦/利托那韦的疾病-药物-药物相互作用。模型预测利托那韦可增加CYP2C19中间代谢者和慢代谢者的伏立康唑暴露,与药品说明书相反;利托那韦和IL-6均升高伏立康唑谷浓度,可能导致CYP2C19表型依赖的过度暴露。

要点

  • 利托那韦可能增加CYP2C19中间代谢者和慢代谢者的伏立康唑暴露,而非降低。
  • COVID-19中IL-6升高与利托那韦均升高伏立康唑谷浓度,交互程度受CYP2C19表型影响。
  • COVID-19患者合用伏立康唑与帕昔洛韦时需谨慎。

核心结论

  • COVID-19诱导的IL-6升高和利托那韦均增加伏立康唑暴露,相互作用程度受CYP2C19表型影响。
  • COVID-19患者合用伏立康唑与帕昔洛韦时需谨慎。

研究设计与样本

  • 建立并验证生理药动学模型,使用伏立康唑、利托那韦和IL-6的PK数据构建,并利用78例COVID-19患者的临床数据进行验证。

主要发现

  • 模型预测伏立康唑、利托那韦和IL-6的PK参数及药物相互作用相关倍数变化在健康受试者和COVID-19患者中预测误差可接受。
  • 模拟显示利托那韦可增加CYP2C19中间代谢者和慢代谢者的伏立康唑暴露,而非降低,与药品说明书相反。
  • 预测的利托那韦暴露在各受试者间相当。
  • 在COVID-19患者中,利托那韦和IL-6均升高伏立康唑谷浓度,可能导致CYP2C19表型依赖的过度暴露。

临床怎么用

  • COVID-19患者合用伏立康唑与帕昔洛韦时需谨慎,尤其关注CYP2C19中间代谢者和慢代谢者的伏立康唑过度暴露风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis superinfection with cytokine storm is associated with increased mortality. This study aimed to establish a physiologically-based pharmacokinetic (PK) model to investigate the disease-drug-drug interactions between voriconazole and nirmatrelvir/ritonavir in patients with COVID-19 with elevated interleukin-6 (IL-6) levels carrying various CYP2C19 phenotypes. The model was constructed and validated using PK data on voriconazole, ritonavir, and IL-6, and was subsequently verified against clinical data from 78 patients with COVID-19. As a result, the model predicted voriconazole, ritonavir, and IL-6 PK parameters and drug-drug interaction-related fold changes in healthy subjects and patients with COVID-19 with acceptable prediction error, demonstrating its predictive capability. Simulations indicated ritonavir could increase voriconazole exposure to CYP2C19 intermediate and poor metabolizers rather than decrease it, in contrast to what is indicated in the drug package insert. However, the predicted ritonavir exposures were comparable across subjects. In patients with COVID-19, both ritonavir and IL-6 increased voriconazole trough concentrations, which may lead to CYP2C19 phenotype-dependent overexposure. In conclusion, COVID-19-induced IL-6 elevation and ritonavir increased voriconazole exposure, and the magnitude of interactions was influenced by CYP2C19 phenotype. Thus, caution is warranted when prescribing voriconazole concomitantly with Paxlovid in patients with COVID-19.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wang P, Liu S, Yang J, et al. Physiologically Based Pharmacokinetic Modeling to Investigate the Disease-Drug-Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID-19 Patients with CYP2C19 Phenotypes. Clin Pharmacol Ther. 2024. PMID: 38429919. doi:10.1002/cpt.3222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。